目的 探讨胆康胶囊联合头孢哌酮钠舒巴坦钠治疗慢性胆囊炎患者的临床效果。方法 选取2016年7月-2017年7月国药东风花果医院收治的慢性胆囊炎患者175例，随机分成对照组（87例）和治疗组（88例）。对照组患者静脉滴注注射用头孢哌酮钠舒巴坦钠，4.0 g加入5%葡萄糖注射液100 mL，2次/d。治疗组患者在对照组的基础上口服胆康胶囊，4粒/次，3次/d。两组患者均治疗2周。观察两组患者临床疗效，同时比较治疗前后两组患者临床症状积分、VAS评分、SF-36评分、肿瘤坏死因子-α（TNF-α）、β-内啡肽（β-EP）和超氧化物歧化酶（SOD）水平及不良反应情况。结果 治疗后，对照组和治疗组临床有效率分别为82.76%和95.45%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者右腹部疼痛，腹胀，恶心、厌油等症状积分均显著下降（P<0.05），且治疗组患者各项症状积分比对照组降低的更明显（P<0.05）。治疗后，两组患者VAS比治疗前均显著降低（P<0.05），SF-36评分显著升高（P<0.05），同时治疗组患者VAS和SF-36评分比对照组患者改善更明显（P<0.05）。治疗后，两组患者TNF-α和β-EP水平显著降低（P<0.05），SOD血清水平显著升高（P<0.05），同时治疗组患者TNF-α、β-EP和SOD血清水平明显优于对照组患者（P<0.05）。治疗期间，对照组患者不良反应发生率为18.39%，显著高于治疗组的5.68%，两组患者比较差异具有统计学意义（P<0.05）。结论 胆康胶囊联合头孢哌酮钠舒巴坦钠治疗慢性胆囊炎患者临床疗效显著，并可改善患者的临床症状，降低不良反应发生率。

Objective To discuss clinical effect of Dankang Capsules combined with cefoperazone sodium and sulbactam sodium in treatment of chronic cholecystitis. Methods Patients (175 cases) with chronic cholecystitis in Sinopharm Dongfeng Huaguo Hospital from July 2016 to July 2017 were randomly divided into control (87 cases) and treatment (88 cases) groups. Patients in the control group were iv administered with Cefoperazone Sodium and Sulbactam Sodium for injection, 4.0 g added into 5% glucose injection 100 mL, twice daily. Patients in the treatment group were po administered with Dankang Capsules on the basis of the control group, 4 grains/times, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom, VAS and SF-36 scores, the TNF-alpha, beta -EP and SOD levels, the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 82.76% and 95.45% respectively, and there were differences between two groups (P<0.05). After treatment, the right abdominal pain, abdominal distension, nausea and disgust edible oil scores in two groups were significantly decreased (P<0.05), and these the clinical symptom scores in the treatment group after treatment were significantly lower than those in the control group (P<0.05). After treatment, the VAS scores in two groups were significantly decreased (P<0.05), SF-36 scores were significantly increased (P<0.05), and the VAS and SF-36 scores in the treatment group after treatment were significantly better than those in the control group (P<0.05). After treatment, the TNF-α and β-EP levels in two groups were significantly decreased (P<0.05), SOD levels were significantly increased (P<0.05), and these indicators in the treatment group after treatment were significantly better than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the control group was 18.39%, which was significantly higher than 5.68% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Dankang Capsules combined with cefoperazone sodium and sulbactam sodium has significant clinical efficacy in treatment of chronic cholecystitis, and can improves the clinical symptom, reduce the incidence of adverse reactions.